SEC Company Response from Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Oct 28, 2015
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Oct. 28, 2015 · CIK: 0001541157 · Accession: 0001144204-15-061107
AI Filing Summary & Sentiment
File numbers found in text: 333-207443
Show Raw Text
CORRESP
1
filename1.htm
AKARI
THERAPEUTICS, PLC
24 West 40th Street
New York, NY 10018
October 28, 2015
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E., Mail Stop 4720
Washington, D.C. 20549
Attention:
Suzanne Hayes
Scott Foley
Re:
Akari Therapeutics, Plc
Registration Statement on Form S-3
Filed on October 16, 2015
File No. 333-207443
Ladies and Gentleman:
Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the “Company”) hereby requests that
the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday, October 30, 2015, at 10:00
a.m., EST, or as soon as thereafter practicable.
Please note that the Company acknowledges the following:
· should the U.S. Securities and Exchange Commission (the “Commission”) or the staff,
acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action
with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Securities and Exchange Commission
October 28, 2015
Page 2
Any questions regarding
this request should be addressed to Jeffrey P. Schultz, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler
Center, 666 Third Avenue, New York, New York 10017, telephone (212) 935-3000.
Thank you very much.
Very truly yours,
AKARI THERAPEUTICS, PLC
/s/ Gur Roshwalb
Gur Roshwalb, M.D.
Chief Executive Officer
cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.
Kenneth R. Koch, Esq.
Jeffrey P. Schultz, Esq.